Top-Rated StocksTop-RatedNASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $31.82 +0.77 (+2.48%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends About Avidity Biosciences Stock (NASDAQ:RNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avidity Biosciences alerts:Sign Up Key Stats Today's Range$30.85▼$32.6350-Day Range$30.70▼$52.5052-Week Range$8.49▼$56.00Volume2.91 million shsAverage Volume1.32 million shsMarket Capitalization$3.80 billionP/E RatioN/ADividend YieldN/APrice Target$64.36Consensus RatingBuy Company OverviewAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More… Avidity Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks43rd Percentile Overall ScoreRNA MarketRank™: Avidity Biosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 647th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avidity Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.52% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 2.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.52% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 2.89%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.43 News SentimentAvidity Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Avidity Biosciences this week, compared to 6 articles on an average week.Search Interest12 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows6 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,006,616.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Stock News HeadlinesInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells 11,151 Shares of StockDecember 20 at 8:49 AM | insidertrades.comW. Michael Flanagan Sells 24,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockDecember 14, 2024 | insidertrades.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 22, 2024 | Brownstone Research (Ad)Promising Advancements and Strategic Growth: A Buy Rating for Avidity BiosciencesDecember 22 at 1:45 PM | markets.businessinsider.comHC Wainwright Begins Coverage on Avidity Biosciences (NASDAQ:RNA)December 22 at 4:27 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Stock Price Up 3.2% - What's Next?December 22 at 3:39 AM | americanbankingnews.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 20 at 5:00 PM | prnewswire.comHC Wainwright & Co. Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationDecember 20 at 4:43 PM | msn.comSee More Headlines RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $9.05 at the start of the year. Since then, RNA shares have increased by 251.6% and is now trading at $31.82. View the best growth stocks for 2024 here. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.14. The biotechnology company earned $2.34 million during the quarter, compared to analyst estimates of $7.09 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 27.66% and a negative net margin of 2,772.45%. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' top institutional shareholders include FMR LLC (14.12%), RTW Investments LP (6.82%), Wellington Management Group LLP (5.89%) and RA Capital Management L.P. (5.28%). Insiders that own company stock include Sarah Boyce, Teresa Mccarthy, Michael F Maclean, W Michael Flanagan, Arthur A Levin and Tamar Thompson. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings11/07/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$64.36 High Stock Price Target$96.00 Low Stock Price Target$45.00 Potential Upside/Downside+102.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,772.45% Pretax Margin-2,772.45% Return on Equity-27.66% Return on Assets-24.56% Debt Debt-to-Equity RatioN/A Current Ratio17.76 Quick Ratio17.76 Sales & Book Value Annual Sales$10.12 million Price / Sales375.25 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book4.71Miscellaneous Outstanding Shares119,309,000Free Float114,918,000Market Cap$3.80 billion OptionableOptionable Beta0.89 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RNA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.